Back to Search Start Over

The when and wheres of CDC25 phosphatases

Authors :
Christine Dozier
Bernard Ducommun
Rose Boutros
Laboratoire de Biologie Cellulaire et Moléculaire du Contrôle de la Prolifération (LBCMCP)
Université Toulouse III - Paul Sabatier (UT3)
Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre de Biologie Intégrative (CBI)
Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS)
Source :
Current Opinion in Cell Biology, Current Opinion in Cell Biology, Elsevier, 2006, 18 (2), pp.185-91. ⟨10.1016/j.ceb.2006.02.003⟩
Publication Year :
2006
Publisher :
Elsevier BV, 2006.

Abstract

The CDC25 phosphatases are key regulators of normal cell division and the cell's response to DNA damage. Earlier studies suggested non-overlapping roles for each isoform during a specific cell cycle phase. However, recent data suggest that multiple CDC25 isoforms cooperate to regulate each cell cycle transition. For instance, although CDC25A was initially thought to exclusively regulate the G(1)-S transition, recent data demonstrate a significant role for CDC25A in the G(2)-M transition. Further evidence demonstrates that in addition to the ATM/ATR-CHK pathway, a p38-MAPKAP pathway is also involved in controlling CDC25 activity during G(2)/M checkpoint activation. Together with the fact that CDC25 overexpression is reported in many cancers, these data highlight the significance of developing specific CDC25 inhibitors for cancer therapy.

Details

ISSN :
09550674
Volume :
18
Database :
OpenAIRE
Journal :
Current Opinion in Cell Biology
Accession number :
edsair.doi.dedup.....d36f92cdae5024e92dfd657ab6eee33d
Full Text :
https://doi.org/10.1016/j.ceb.2006.02.003